The first court fight over the old miscarriage drug DES and alleged links to breast cancer didn't last long. On the second day of the trial, Eli Lilly ($LLY) settled with the four plaintiffs, who had claimed that the drug, used by their mother during pregnancy, caused them to develop the disease.
Around the same time Eli Lilly and Boehringer Ingelheim were boasting of a slate of Phase III successes for their critical diabetes therapy empagliflozin, the two pharma giants put out the word that they were parting ways on another key partnership for a diabetes drug that also figured prominently in their big R&D pact.
Eli Lilly ($LLY) and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its diabetes treatment empagliflozin.
Eli Lilly and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its SGLT-2 treatment empagliflozin this morning, taking a big step toward a new drug application expected later in the year.
Eli Lilly ($LLY) sees better-than-expected times ahead, at least for its bottom line. The drugmaker issued a 2013 profits forecast that surpassed analyst estimates, despite sales still suffering from the patent cliff. What's the secret sauce? Cost-cutting.
Look--out on the horizon. It's not a bird, or a plane or a megadeal of the 2009 variety. It's a superdeal, a buyout of $10 billion or more. And according to analysts, pharma is about to hopscotch through a series of them.
Most people take vitamins to boost their energy or protect against colds. But Eli Lilly ($LLY) is hoping vitamin B12 will protect it from losing up to $3.5 billion in sales a year.
Fifty to 80 years ago, the synthetic estrogen DES was commonly prescribed to women who were at risk for miscarriage and premature births. Now dozens of their daughters who have developed breast cancer are suing drugmakers.
Don't be fooled by the overflow of news on stock swings and megabucks involved in biotech; many people--and I would guess most--become enamored with this industry because of the promise of transforming scientific discoveries into new therapies. Bank on 2013 being a year when real innovators in life sciences with bold ideas look like smart businesspeople too. Read more >>
Call it gilding the Lilly. For nearly two decades, the Indianapolis-based Eli Lilly is believed to have forked over bribes to officials in countries like China, Russia and Brazil. In return it pocketed millions of dollars worth of business. Now it will pay up again, but this time to the U.S. government.